Kura Oncology Form 144 for 8,180-share stock sale

Kura Oncology filed a Form 144 notice for a proposed sale of 8,180 shares of its common stock.

Rhea-AI Filing Summary

Kura Oncology filed a Form 144 notice for a proposed sale of 8,180 shares of its common stock. The shares have an aggregate market value of $69,284.60 and are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ.

The filing states that Kura Oncology had 88,309,441 common shares outstanding as of the time referenced. All 8,180 shares to be sold were acquired on 01/27/2026 from the issuer via restricted stock unit (RSU) transactions on that same date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the KURA Form 144 filing disclose?

The Form 144 for Kura Oncology (KURA) discloses a proposed sale of 8,180 common shares. These shares, valued in total at $69,284.60, are planned to be sold on the NASDAQ through Morgan Stanley Smith Barney LLC.

How many KURA shares are covered by this Form 144 and what is their value?

The notice covers 8,180 Kura Oncology common shares with an aggregate market value of $69,284.60. This value is based on the market price used in the Form 144 and applies specifically to this planned sale.

How were the KURA shares in this Form 144 acquired?

The 8,180 Kura Oncology shares were acquired on 01/27/2026 via restricted stock units (RSUs) from the issuer. Multiple RSU entries on that date collectively match the total number of shares indicated for the proposed sale.

What does the Form 144 say about KURA’s shares outstanding?

The Form 144 notes that 88,309,441 Kura Oncology common shares were outstanding at the referenced time. This figure provides context for the size of the planned 8,180-share sale relative to the company’s total common stock.

Which broker and exchange are involved in the KURA Form 144 sale?

The proposed sale in the Form 144 is through Morgan Stanley Smith Barney LLC Executive Financial Services, located in New York. The 8,180 common shares of Kura Oncology are planned to be sold on the NASDAQ stock exchange.

What representation does the seller make in the KURA Form 144?

The person for whose account the Kura Oncology shares are to be sold represents that they do not know any undisclosed material adverse information about the issuer’s current or prospective operations at the time of signing the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 09:30 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002051106
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KURA ONCOLOGY, INC.
SEC File Number	001-37620
Address of Issuer	4930 Directors Place, Suite 500 San Diego CALIFORNIA 92121
Phone	(858)-500-8800
Name of Person for Whose Account the Securities are To Be Sold	LEONI MOLLIE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	8180	69284.6	88309441	01/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/27/2026	RSU	Issuer			3655	01/27/2026	N/A
Common Stock	01/27/2026	RSU	Issuer			2233	01/27/2026	N/A
Common Stock	01/27/2026	RSU	Issuer			951	01/27/2026	N/A
Common Stock	01/27/2026	RSU	Issuer			1341	01/27/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	01/27/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Teresa Bair, Attorney-in-fact for Mollie Leoni
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)